• Home
  • About Us
  • Contact
  • Your Account
  • Subscribe
Monday, August 15, 2022
  • Login
Alternatives Watch
  • Subscribe
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
No Result
View All Result
  • Subscribe
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
No Result
View All Result
Alternatives Watch
No Result
View All Result

TPG Capital launches new pharma company

Susan BarretobySusan Barreto
September 23, 2020
in Manager News, Private Equity
TPG Capital launches new pharma company

Retha Ferguson/Pexels

ShareTweetShareSendSend

Private equity platform TPG Capital formed Ellodi Pharmaceuticals, a new specialty pharma company dedicated to the treatment of a chronic, allergic inflammatory disease of the esophagus.

The disease, eosinophilic esophagitis (EoE), is rare and effects only 57 out of 100,000 patients. The exact cause is unknown, but it is believed to be triggered by a variety of stimuli including certain foods and environmental allergens.

Ellodi is dedicated to a new therapy (APT-1011) to treat the disease, which is in Phase 3 development and is a spin out of Adare Pharmaceuticals. The new entity follows TPG Capital’s sale of Adare Pharmaceuticals specialty CDMO pharmaceutical technology and microbiome business to Thomas H. Lee Partners and Frazier Healthcare Partners.

“Beginning a decade ago with our acquisition of Eurand and since the founding of Adare with the carve-out from Allergan in 2015, we have been proud to partner with John Fraher and the entire management team to build a leading global CDMO,” said Todd Sisitsky, co-managing partner of TPG Capital. “Through the application of its innovative science and proprietary drug delivery and microbiome technologies, Adare products have helped treat millions of patients through its partnerships with customers across the pharmaceutical landscape. We wish the Adare Pharma Solutions team continued success with its new partners.”

The terms of the transaction were not disclosed.

As part of the announcement, Adare’s Global Head of Specialty Pharma, Troy Hamilton, will assume the role of Ellodi Pharmaceuticals’ CEO. He has held several executive and gastroenterology-related commercial leadership roles focused on functional gastrointestinal disorders, inflammatory bowel disease, EoE, short bowel syndrome, rare pediatric cholestasis, and acid-peptic disorders. Hamilton will continue to be supported by the program’s existing clinical team

“We have been privileged to partner with the Adare team for over a decade and are equally excited to continue to invest in the development of APT-1011, with the launch of Ellodi Pharmaceuticals, whose leadership team have spearheaded the program,” said John R. Schilling, MD and partner at TPG Capital. “Our clinical data provide diagnostic, histologic, and patient-reported evidence of safety and efficacy in the treatment of the eosinophilic esophagitis. We look forward to completing the development of APT-1011 and the opportunity to bring this important therapeutic to the patients who are suffering from the disease.”

Tags: Life Sciences
ShareTweetShareSendSend
Previous Post

FrontWell raises $350m for new private credit fund

Next Post

KKR’s stellar 2020 continues

Related Posts

Illinois pension adds more than $1.5 billion to alts
Investor News

Illinois pension adds more than $1.5 billion to alts

Conversus StepStone opens venture/growth fund
Private Equity

Conversus StepStone opens venture/growth fund

Pomona closes secondary fund at $2.6bn
Manager News

Pomona closes secondary fund at $2.6bn

Carlyle announces another departure
Private Equity

Carlyle announces another departure

Texas Teachers adds $785m to private markets
Pensions

Texas Teachers adds $785m to private markets

Next Post
KKR’s stellar 2020 continues

KKR’s stellar 2020 continues

Log In

Lost your password?

Recent Stories

AW Deal Watch: Blockbuster deals continue in private equity land

AW Deal Watch: Blockbuster deals continue in private equity land

KCERA ups private real estate

KCERA ups private real estate

Illinois pension adds more than $1.5 billion to alts

Illinois pension adds more than $1.5 billion to alts

Pennsylvania Public School Employees Retirement System

PSERS adds to alts 

Search the AW Archives

No Result
View All Result

Download

Alternatives Watch

© 2019-2022, All Rights Reserved  |  BMV Digital

Navigate Site

  • Subscribe
  • Hedge Funds
  • Private Equity
  • Private Credit
  • RE/Infrastructure
  • Investor News
  • Research

Follow Us

No Result
View All Result
  • Subscribe
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
Log In

© 2019-2022, All Rights Reserved  |  BMV Digital

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Be an alts insider

Start your days in the know with our free newsletter

No, I don't want to be an alts insider

Thank

You!

Follow us
on LinkedIn

Cookie Consent
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie Settings Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo